Literature DB >> 659588

Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis.

N Aoki, M Moroi, Y Sakata, N Yoshida, M Matsuda.   

Abstract

A patient who suffered a recurring thrombosis over the last 15 yr has been investigated. The only abnormality found in this patient was a significantly depressed level of plasminogen activity in plasma. In spite of the depressed plasminogen activity, the patient was found to have a normal level of plasminogen antigen concentration. It was calculated that the activity per milligram of plasminogen of the patient was approximately one-half the values of normal subjects. The same discrepancy between biological activity and antigen concentration was found in the other members of the kindred. A niece was found to have practically no plasminogen activity but possessed a normal concentration of plasminogen antigen. Both her parents were found to have approximately half the normal plasminogen activity and normal antigen levels. These studies suggested that the molecular abnormality was inherited as an autosomal characteristic, and the family members who had half the normal levels of activity with normal plasminogen antigen were heterozygotes whereas the one with practically no plasminogen activity was homozygote. Subsequent studies showed that the pattern of gel electrofocusing of purified plasminogen of the heterozygotes consisted of 10 normal bands and 10 additional abnormal bands, each of which had a slightly higher isoelectric point than each corresponding normal component. This indicates that plasminogen of the heterozygote is a mixture of normal and abnormal molecules in an approximately equal amount, which was substantiated by active site titration of purified plasminogen preparations obtained from the propositus and a normal individual. The gel electrofocusing pattern of the homozygote consisted of abnormal bands only. The defect is a hereditary abnormality of plasminogen.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659588      PMCID: PMC372639          DOI: 10.1172/JCI109034

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  THE INFLUENCE OF INORGANIC SALTS ON PLASMA ANTITHROMBIN ACTIVITY.

Authors:  F C MONKHOUSE
Journal:  Thromb Diath Haemorrh       Date:  1963-07-15

2.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

3.  Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.

Authors:  I M NILSSON; H KROOK; N H STERNBY; E SODERBERG; N SODERSTROM
Journal:  Acta Med Scand       Date:  1961-03

4.  The mechanism of clot dissolution by plasmin.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1959-07       Impact factor: 14.808

5.  Methods for the evaluation of human fibrinolysis; studies with two combined technics.

Authors:  K N VON KAULLA; R L SCHULTZ
Journal:  Am J Clin Pathol       Date:  1958-02       Impact factor: 2.493

6.  Thrombotic disorders with increased levels of antiplasmin and antiplasminogen.

Authors:  R L NAEYE
Journal:  N Engl J Med       Date:  1961-11-02       Impact factor: 91.245

7.  A new method for the determination of fibrinogen in small samples of plasma.

Authors:  O D RATNOFF; C MENZIE
Journal:  J Lab Clin Med       Date:  1951-02

8.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

9.  The behavior of alpha2-plasmin inhibitor in fibrinolytic states.

Authors:  N Aoki; M Moroi; M Matsuda; K Tachiya
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more
  40 in total

1.  The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities.

Authors:  R L Nachman
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

2.  Plasminogen with type-I mutation is polymorphic in the Japanese population.

Authors:  S Kikuchi; Y Yamanouchi; L Li; K Kobayashi; H Ijima; R Miyazaki; S Tsuchiya; H Hamaguchi
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

Review 3.  The human plasma fibrinolytic system: regulation and control.

Authors:  K C Robbins
Journal:  Mol Cell Biochem       Date:  1978-08-16       Impact factor: 3.396

Review 4.  Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation.

Authors:  Toshiyuki Miyata; Rina Kimura; Yoshihiro Kokubo; Toshiyuki Sakata
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

5.  Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis.

Authors:  A Ichinose; E S Espling; J Takamatsu; H Saito; K Shinmyozu; I Maruyama; T E Petersen; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

6.  The plasminogen polymorphism in South African Negro populations: genetics and anthropogenetics.

Authors:  H W Hitzeroth; U Skoda; E du Toit; G Mauff
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

Review 7.  Plasminogen deficiency.

Authors:  Tiraje Celkan
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

8.  No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome.

Authors:  Toshiyuki Miyata; Yumiko Uchida; Yoko Yoshida; Hideki Kato; Masanori Matsumoto; Koichi Kokame; Yoshihiro Fujimura; Masaomi Nangaku
Journal:  Int J Hematol       Date:  2016-05-18       Impact factor: 2.490

9.  Familial protein S deficiency is associated with recurrent thrombosis.

Authors:  P C Comp; R R Nixon; M R Cooper; C T Esmon
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.